Loading...
Loading...
ChemoCentryx, Inc.
CCXI reports that GlaxoSmithKline
GSK announced today that the
first of four Phase III studies, the SHIELD-1 study, investigating vercirnon,
an inhibitor of the chemokine receptor known as CCR9, in patients with
moderate-to-severe Crohn's disease did not achieve the primary endpoint of
improvement in clinical response and the key secondary endpoint of clinical
remission. The rates of serious adverse events and withdrawals due to adverse
events were similar among all treatment groups including the placebo group,
with a trend in dose-dependent increases in overall adverse event rates. GSK
has indicated that it intends to continue to explore the safety and efficacy
results to inform decisions about the clinical development program for
vercirnon. New recruitment and dosing in the ongoing clinical program has been
suspended pending further review of the SHIELD-1 results.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in